Alpha Cognition vs LENZ Therapeutics
ACOG and LENZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACOG and LENZ compare
Alpha Cognition is the larger company, worth 1.4 times as much as LENZ Therapeutics ($181M against $130M).
Alpha Cognition keeps more of each dollar of sales as profit, with a net margin of −145% compared with −587% at LENZ Therapeutics.
LENZ Therapeutics scores higher on the StockData Score (9 against 6 for Alpha Cognition), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACOG | LENZ |
|---|---|---|
| Size and price | ||
| Market cap | $181M | $130M |
| Share price | $8.30 | $4.13 |
| Change, 1 year | 35.6% | −83.8% |
| Change, 5 years | −63.3% | −94.7% |
| Beta (5Y) | 0.34 | 1.08 |
| Employees | 72 | 152 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.9× | 6.0× (better) |
| P/B | 3.7× | 0.6× (better) |
| FCF yield | −17.1% (better) | −88.2% |
| Fair value | $5.01 | $7.62 |
| Margin of safety | −65.7% | 45.8% (better) |
| Growth | ||
| Revenue growth (TTM) | – | 330% |
| Profitability | ||
| Gross margin | 92.9% | – |
| Operating margin | −147% (better) | −632% |
| Net margin | −145% (better) | −587% |
| FCF margin | −153% (better) | −533% |
| Return on equity | −72.9% | −59.2% (better) |
| Return on invested capital | −684% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.13 | 13.55 (better) |
| Altman Z-score | 4.50 (better) | 2.01 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 48.7% | 110% |
| Held by insiders | 5.3% | 6.7% |
| Insider net buying, 12 months | $8.3M (better) | −$8.8M |
| Short interest, % of float | 2.0% | 24.1% |
Go deeper
- ACOG stock overview
- ACOG income statement
- ACOG valuation and score
- LENZ stock overview
- LENZ income statement
- LENZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.